Medical Condition News

RSS

Adynxx initiates AYX1 Phase 2 study to prevent post-surgical pain

Adynxx, a clinical-stage pharmaceutical company developing a first-in-class platform of therapeutics to address pain at its molecular roots, announced today that the first patient was dosed in a Phase 2 study of its lead investigational drug candidate for the prevention of post-surgical pain, AYX1.

26 Feb 2013

LabCorp introduces GeneSeq: Carido for familial cardiac disease

Laboratory Corporation of America Holdings today announced it has launched its clinical next generation sequencing assay, GeneSeq: Cardio for genetic causes of familial cardiac disease.

26 Feb 2013

Bayer receives FDA approval for Stivarga to treat advanced gastrointestinal stromal tumors

The U.S. Food and Drug Administration today expanded the approved use of Stivarga (regorafenib) to treat patients with advanced gastrointestinal stromal tumors (GIST) that cannot be surgically removed and no longer respond to other FDA-approved treatments for this disease.

26 Feb 2013

Survey finds 65% of Missouri salons would allow pre-teens to use tanning beds

A survey of tanning salon operators in Missouri shows that 65 percent would allow children as young as 10 to 12 years old to use tanning beds. That's despite evidence that any tanning bed use increases the risk of all skin cancers, including melanoma, the deadliest form of skin cancer, later in life.

26 Feb 2013

Avaxia initiates AVX-470 Phase 1b clinical study in ulcerative colitis

Avaxia Biologics, Inc., a clinical-stage biopharmaceutical company developing gut-targeted therapeutics, announced today that the first patient has been dosed in a Phase 1b clinical study of AVX-470, an oral anti-TNF antibody, for the treatment of ulcerative colitis.

25 Feb 2013

Early lymphoid progenitors thrive in an osteoblastic niche: Study

The Children's Medical Center Research Institute at UT Southwestern has deepened the understanding of the environment within bone marrow that nurtures stem cells, this time identifying the biological setting for specialized blood-forming cells that produce the infection-fighting white blood cells known as T cells and B cells.

25 Feb 2013

Researchers to present new results for Merck's allergy immunotherapy tablets at AAAAI meeting

Merck, known as MSD outside the United States and Canada, today announced that researchers will present new data analyses of the safety and efficacy of the company's investigational allergy immunotherapy tablets (AITs) for ragweed pollen (Ambrosia artemisiifolia) and grass pollen (Phleum pratense) at the 2013 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting.

25 Feb 2013

Distinct bone marrow niches can nurture different types of blood stem cells

In research that could one day improve the success of stem cell transplants and chemotherapy, scientists have found that distinct niches exist in bone marrow to nurture different types of blood stem cells.

25 Feb 2013

Better representation of elderly patients in phase III trials can improve evidence-based treatment

The median age of patients diagnosed with advanced non-small-cell lung cancer (NSCLC) has steadily increased over the recent years and is presently 70 years. Despite this, the elderly are significantly underrepresented in clinical trials.

25 Feb 2013

Dana-Farber launches iPhone app that helps fight cancer

Dana-Farber Cancer Institute has launched a free, easy-to-use iPhone app that provides recipes and nutrition information that can be searched by cancer patients in accordance with their needs.

25 Feb 2013

GLP-1 may increase risk of hospitalization for people with acute pancreatitis

People who take the newest class of diabetes drugs to control blood sugar are twice as likely as those on other forms of sugar-control medication to be hospitalized with pancreatitis, Johns Hopkins researchers report.

25 Feb 2013

Non-surgical weight loss device clinical trial completes enrollment

ReShape Medical® Inc announced today that it has completed enrollment in the pivotal clinical trial for the ReShape Duo® Intragastric Balloon, one of the first non-surgical weight loss devices developed for the U.S. market.

25 Feb 2013

Lung cancer screening could avert 12,000 deaths each year in the US

Screening for lung cancer with low-dose computed tomography (LDCT) in all screening-eligible current and former smokers has the potential to avert approximately 12,000 lung cancer deaths each year in the United States.

25 Feb 2013

Harmful effects of stress may be key to managing chronic pain

For chronic pain sufferers, such as people who develop back pain after a car accident, avoiding the harmful effects of stress may be key to managing their condition.

25 Feb 2013

Circassia announces results from ToleroMune cat allergy phase II clinical study

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the results of a phase II clinical study showing that a short course of just four doses of its ToleroMune cat allergy therapy maintained improvements in patients' symptoms two years after the start of treatment.

25 Feb 2013

Greek and Spanish patients can now read EAU Patient Information in their native language

Greek and Spanish-speaking patients with kidney or ureteral stones can now read EAU Patient Information in their native language. The Endourology, Laparoscopy and Urotechnology Section of the Hellenic Urologic Association (HUA) has provided the Greek translation and the Spanish translation is the result of a collaboration between the Spanish Association of Urology (AEU) and the Dominican Republic Society of Urology (SDU).

25 Feb 2013

Omalizumab fast, safe and well-tolerated in teens and adults with chronic spontaneous urticaria

An international team of researchers has found that a once-a-month, high-dose injection of a commonly used asthma drug is highly effective in treating teens and adults chronically afflicted with hives and severe, itchy rash. The drug, omalizumab, was tested on 323 people at 55 medical centers for whom standard antihistamine therapy failed to quell their underlying, allergy-like reaction, known as chronic idiopathic urticaria or chronic spontaneous urticaria.

25 Feb 2013

Novel anti-cancer drug conjugates to be evaluated by Ablynx and Spirogen

Ablynx [Euronext Brussels: ABLX] and Spirogen Ltd. announce a research collaboration to evaluate the potential of a novel anti-cancer drug conjugate combining Spirogen's proprietary cytotoxic drugs, pyrrolobenzodiazepines (PBD), and associated linker technology, with Nanobodies® generated using Ablynx’s proprietary technology platform.

25 Feb 2013

PneumRx initiates RePneu LVRC pivotal study in severe emphysema

PneumRx, Inc., a leader in interventional pulmonology, announced the first U.S. patients treated with PneumRx's Lung Volume Reduction Coils (LVRCs) for severe emphysema.

25 Feb 2013

Ampio to initiate dose escalation run-in study for treatment of knee osteoarthritis

Ampio Pharmaceuticals, Inc. announced today that it's Phase III clinical study of Ampion™ for the treatment for osteoarthritis of the knee will include a dose-escalation run-in study as recommended by the FDA.

25 Feb 2013